NAD+ Injections: What They Are, What the Evidence Shows, and What to Expect

NAD+ injections have become one of the most discussed offerings in wellness clinics and longevity-focused medical practices. The category ranges from intravenous infusions running over several hours to smaller subcutaneous injections that can be self-administered at home. Both deliver nicotinamide adenine dinucleotide into the bloodstream rather than relying on oral precursors that the body converts into NAD+. The clinical interest is grounded in real biochemistry: NAD+ declines by approximately 50% between ages 20 and 60, and that decline has documented consequences for mitochondrial energy production, DNA repair capacity, and sirtuin-regulated aging processes. The question worth asking honestly is what the injectable route actually adds over oral alternatives, and what the evidence supports at a clinically meaningful level. A foundational review of the NAD+ research landscape is available in the NIH StatPearls chapter on NAD+ biochemistry. For the broader context of how NAD+ relates to peptide therapy, the article on NAD+ and Peptide Therapy covers the complementary mechanisms in depth.

What NAD+ Injections Are: The Two Forms

The term NAD+ injections encompasses two meaningfully different delivery approaches that share a compound but differ substantially in dose, setting, side effect profile, and clinical purpose.

Intravenous NAD+ Infusions

Intravenous NAD+ is administered in a clinical setting, typically at doses of 250 to 1,000 mg delivered over 2 to 4 hours via slow IV drip. The slow delivery rate is not optional. IV NAD+ produces extracellular NAD+ concentrations that, when delivered too rapidly, trigger a range of uncomfortable responses including nausea, flushing, chest tightness, abdominal cramping, and malaise. These side effects are rate-dependent and largely related to the pro-inflammatory response created by supraphysiological extracellular NAD+ concentrations. Slowing the infusion rate reduces them substantially. In clinical settings, patients commonly sit for a full 2 to 4 hours to complete an infusion at a tolerable pace.

Subcutaneous NAD+ Injections

Subcutaneous NAD+ injections use lower doses, typically 25 to 100 mg per injection, administered under the skin rather than directly into the bloodstream. The lower concentration and slower absorption from subcutaneous tissue produce a milder side effect profile than IV infusions. Some protocols involve daily subcutaneous injections as an ongoing maintenance approach rather than periodic IV sessions. The trade-off is that peak blood NAD+ concentrations are lower than with IV delivery, which may affect how robustly cellular NAD+ levels are replenished.

The Biochemistry Question: Does Injected NAD+ Actually Enter Cells?

This is the most important and most frequently overlooked question in any conversation about NAD+ injections, and it deserves a direct answer.

NAD+ is a large molecule that does not readily cross cell membranes on its own. When NAD+ is delivered into the bloodstream, the primary pathway for cellular uptake involves enzymatic breakdown of extracellular NAD+ into precursor molecules, principally NMN (nicotinamide mononucleotide), which can then enter cells via specific transporters and be converted back to NAD+. The direct delivery of NAD+ into the bloodstream may therefore produce effects that are biochemically similar to elevating circulating NMN or NR rather than directly replenishing intracellular NAD+.

This is not a reason to conclude that NAD+ injections are ineffective. Blood NAD+ levels are reliably elevated by intravenous administration, as confirmed in the retrospective tolerability study published in PMC in 2025 comparing IV NAD+ and IV NR in a real-world clinical population. The question is whether this blood-level elevation translates to meaningful intracellular NAD+ replenishment in the tissues that matter most, particularly muscle, liver, and brain. Current data does not yet answer this question with the rigor that would support definitive conclusions.

What the Evidence for NAD+ Injections Actually Shows

The honest characterization of the evidence for injectable NAD+ specifically is that it is limited and primarily observational or mechanistic. This is a meaningfully different situation from the evidence for oral NAD+ precursors, where multiple Phase 2 human randomized controlled trials exist. The clinical research on NAD+ injections is worth reviewing category by category.

Energy, Fatigue, and Recovery

IV NAD+ is commonly marketed for energy enhancement and recovery. The mechanistic rationale is clear: NAD+ is essential for mitochondrial energy production, and raising NAD+ levels should theoretically improve cellular energy output. However, a 2023 systematic review in Nutrients examining intravenous NAD+ supplementation and fatigue outcomes did not find controlled clinical trial data confirming subjective energy or fatigue benefits. Patient-reported improvements are common in clinical settings, but subjective improvement in the absence of controlled trial data cannot distinguish treatment effect from placebo response. The placebo response for energy and wellness interventions is well-documented to be substantial.

Cognitive Function and Brain Health

NAD+ has documented roles in neuronal energy metabolism and neuroprotection. Several ongoing trials are investigating oral NAD+ precursors for cognitive outcomes. The specific evidence for injectable NAD+ in cognitive function is largely anecdotal in humans. Dr. Lisa Mosconi’s research group has documented NAD+ metabolism changes during menopause and their relationship to cognitive transition, but this research does not specifically validate IV NAD+ as a cognitive intervention. The evidence gap between mechanistic rationale and clinical proof is currently large for cognitive endpoints.

Addiction and Withdrawal Support

IV NAD+ therapy for substance use disorder has a longer clinical history than its other applications, dating to early clinical observations in the 1960s. Some practitioners have incorporated IV NAD+ into detox protocols for alcohol and opioid withdrawal. The evidence base remains limited to case reports and small, uncontrolled studies. No large randomized controlled trials have confirmed these effects. JAMA Psychiatry published a 2022 commentary noting that claims around NAD+ therapy for addiction recovery outpace the current controlled evidence.

Liver Health and Metabolic Function

NAD+ metabolism and liver health are closely connected. The liver is a primary site of NAD+ biosynthesis, and NAD+ depletion is associated with fatty liver disease in animal models. A 2021 review in Nature Reviews Molecular Cell Biology by Yoshino and colleagues covers the metabolic roles of NAD+ comprehensively. However, the specific clinical evidence for IV NAD+ in human liver disease is limited, while some evidence for NR and NMN in metabolic outcomes exists from oral trials.

Regulatory Status of NAD+ Injections

NAD+ injections are not FDA-approved for any therapeutic indication. They are available in clinical settings as off-label preparations from licensed 503A compounding pharmacies under physician supervision. This regulatory situation has two important implications for patients.

First, there are no standardized quality requirements for compounded NAD+ beyond the general Good Manufacturing Practice standards for licensed 503A pharmacies. The FDA has issued warnings about contamination risks with NAD+ injectables, specifically noting that some compounders have used food-grade rather than pharmaceutical-grade ingredients. Requesting a Certificate of Analysis from the pharmacy and confirming that pharmaceutical-grade NAD+ is being used is appropriate due diligence before initiating any IV protocol.

Second, the absence of FDA approval means there are no standardized dosing guidelines. Protocols across clinical practices vary considerably in dose, frequency, and route. A licensed provider selecting a protocol is drawing on clinical experience and available mechanistic and observational data rather than an FDA-reviewed evidence package. This context does not make NAD+ injections inappropriate. It does mean that the choice of provider and pharmacy carries more weight than it would for a compound with established regulatory guidance. For a broader understanding of how the regulatory framework for compounded treatments works, the article on Are Peptides Legal in the US explains the 503A compounding system in detail.

What to Expect: Side Effects and the Typical Session

Anyone considering IV NAD+ injections should understand the side effect profile before the first session, because the infusion experience is distinctive and can be surprising if not anticipated.

The most common IV NAD+ side effects during infusion are nausea, flushing, headache, chest tightness or pressure sensation, abdominal cramping, and a general feeling of malaise. These effects are dose-dependent and rate-dependent. At lower doses or slower infusion rates they are typically mild. At higher doses (500 mg or above) administered at faster rates, they can be significant enough that some patients find their first session uncomfortable. The mechanism behind these infusion reactions is the pro-inflammatory environment created by high extracellular NAD+ concentrations. Slowing the infusion rate almost always reduces them.

For subcutaneous NAD+ injections at lower doses, the side effect profile is considerably milder. Injection site reactions including redness, swelling, and mild pain are the most common complaint. Nausea and flushing occur more frequently at doses above 250 to 300 mg and are less common at the lower doses typical of the subcutaneous route.

Who Should Not Receive NAD+ Injections

Because NAD+ is involved in cellular proliferation and DNA repair pathways, active malignancy is a clinical concern. NAD+ is required for PARP enzyme activity, and PARP inhibitors are actually used in oncology to slow certain cancer cell growth. The implication for patients with active cancer is that NAD+ elevation could theoretically support cancer cell metabolism. This is not a confirmed clinical risk at the doses used in wellness protocols, but it is a reason active malignancy history warrants careful provider evaluation before any NAD+ supplementation protocol, oral or injectable. Patients with cardiovascular disease should discuss the infusion-rate-dependent cardiovascular sensations with a provider before beginning IV NAD+. A full evaluation is the appropriate starting point, as outlined in the companion article, What Labs Do You Need Before Starting Peptide Therapy.

NAD+ Injections in the Context of a Broader Longevity Protocol

NAD+ injections are rarely the only intervention in a comprehensive longevity or hormone optimization protocol. They are most commonly discussed alongside GH-stimulating peptides, testosterone optimization, and mitochondrial support strategies as complementary approaches addressing different biological layers. GH secretagogues like Sermorelin address the GH-IGF-1 axis and its downstream effects on body composition and recovery. NAD+ addresses the intracellular energy and genomic maintenance layer. Neither replaces the other, and a provider evaluating both as part of a comprehensive protocol is working from a conceptually coherent framework even though no controlled trial has studied the combination directly. The article on Peptides and Healthy Aging covers the broader evidence landscape for longevity-focused protocols. For patients who want to understand what an initial evaluation looks like before beginning any protocol, the First Peptide Therapy Consultation guide describes the process step by step.